Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase FusionDiseaseMyeloid/Lymphoid Neoplasia with Eosinophilia and TC FusionSubgroupFGFR1 RearrangementJAK2 rearrangementPDGFRA rearrangementPDGFRB rearrangementICD10D47.1MeSHHypereosinophilic SyndromeSequenceChemotherapyChemo-substanceImatinibPemigatinibRuxolitinibChemo-substanceImatinibPemigatinibRuxolitinibChemo-substanceImatinibPemigatinibRuxolitinibChemo-substanceImatinibPemigatinibRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronNo. Substances2Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksAlopeciaAnemia Hb below 8g/dlArthalgiaDiarrheaEmetogenicityEmetogenicity (ASCO)Hand-Foot SyndromeHyperphosphatemiaHyponatremiaHypophosphatemiaMucositisNeutropeniaThrombocytopenia below 50 000/µlVisual Disturbances only studiesPublicationAuthorGotlib JJawhar MSchwaab JDiseaseMyeloische Neoplasien mit EosinophilieMyeloische Neoplasien mit Eosinophilie mit JAK2-Rearrangement (PCM1-JAK2, BCR-JAK2 und ETV6-ABL1 Fusion)Myeloische Neoplasien mit Eosinophilie und FGFR1 RearrangementOriginDivision of Hematology, Stanford Cancer Institute / Stanford University School of Medicine, Stanford, FIGHT-203 trialUniversity Hospital Mannheim, Heidelberg University, Mannheim, GermanyUniversity Medical Centre Mannheim, Mannheim, GermanyProtocols in Revision 3 protocols foundProtocols under revision.Imatinib 400, Myeloid/Lymphoid Neoplasia with Eosinophilia and TK Fusion. (PID2100 V1.0)Pemigatinib 13.5, Myeloid/Lymphoid Neoplasia with Eosinophilia and TK Fusion (PID2114 V1.0)Ruxolitinib 15, Myeloid/Lymphoid Neoplasia with Eosinophilia and TK Fusion (PID2115 V1.0)
